Advertisement
UK markets close in 7 hours 14 minutes
  • FTSE 100

    7,954.57
    +22.59 (+0.28%)
     
  • FTSE 250

    19,786.92
    -23.74 (-0.12%)
     
  • AIM

    741.52
    -0.59 (-0.08%)
     
  • GBP/EUR

    1.1675
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.2591
    -0.0047 (-0.37%)
     
  • Bitcoin GBP

    56,162.93
    +839.06 (+1.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.74
    +0.39 (+0.48%)
     
  • GOLD FUTURES

    2,195.10
    +4.50 (+0.21%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,490.58
    +13.49 (+0.07%)
     
  • CAC 40

    8,237.54
    +32.73 (+0.40%)
     

Is the Worst Over for Novavax?

Is the Worst Over for Novavax?

In the early days of the COVID-19 pandemic, Novavax (NASDAQ: NVAX) took center stage. The biotech company became one of the first to enter clinical trials with a coronavirus vaccine candidate. Novavax's vaccine launched a year after those of the company's rivals, meaning Novavax missed out on the biggest revenue opportunity.